Pharmacogenetics of response to statins: where do we stand?

TitlePharmacogenetics of response to statins: where do we stand?
Publication TypeJournal Article
Year of Publication2005
Authorsvan der Zee, A-HMaitland-, Boerwinkle, E
JournalCurr Atheroscler Rep
Volume7
Issue3
Pagination204-8
Date Published2005 May
ISSN1523-3804
KeywordsCarrier Proteins, Cholesterol Ester Transfer Proteins, Cholesterol, LDL, Coronary Artery Disease, Glycoproteins, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Pharmacogenetics, Polymorphism, Genetic
Abstract

Cardiovascular disease is one of the leading causes of death, especially in developed countries. Blood cholesterol lowering by way of statin therapy is a common risk-lowering therapy. The risk reduction for coronary artery disease for patients using statins is 27%. These reductions, however, are average effects for all patients included in the trials. There is notable interindividual variation in response to statins, and the origins of this variation are poorly understood. Pharmacogenetics seeks to determine the role of genetic factors in variation of drug response. In patients with primary hypercholesterolemia, 23 studies have examined the effects of genetic polymorphisms at 20 different loci on the lipid response to statin treatment, and 18 studies examined genetic polymorphisms involved in the benefits of statin therapy in the prevention of cardiovascular disease. Even though many studies have been performed, few results have been replicated. It is our contention that larger sample sizes and consideration of multiple genes are needed in the field of pharmacogenetics of statin response.

Alternate JournalCurr Atheroscler Rep
PubMed ID15811254